Robert W. Baird analyst Eric Coldwell maintained a Buy rating on PRA Health Sciences (NASDAQ:PRAH) on Monday, setting a price target of $160, which is approximately 9.22% above the present share price of $146.49.
Coldwell expects PRA Health Sciences to post earnings per share (EPS) of $0.80 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in PRA Health Sciences, with an average price target of $172.
The analysts price targets range from a high of $196 to a low of $160.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $873.46 million and a net profit of $97.23 million. The company's market cap is $9.46 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 61.47% success rate.
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights; and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC.